FYERS
Home
/
Stocks
/
Profit Loss
/
CORONA Remedies Profit & Loss

CORONA Remedies Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
₹441 Cr₹422 Cr₹353 Cr₹342 Cr₹361 Cr₹347 Cr₹294 Cr₹298 Cr₹314 Cr
₹2 Cr₹3 Cr₹4 Cr₹2 Cr₹2 Cr₹2 Cr₹1 Cr₹76 L₹2 Cr
₹444 Cr₹426 Cr₹357 Cr₹345 Cr₹363 Cr₹349 Cr₹295 Cr₹298 Cr₹316 Cr
₹360 Cr₹343 Cr₹301 Cr₹269 Cr₹292 Cr₹286 Cr₹250 Cr₹238 Cr₹256 Cr
₹98 Cr₹96 Cr₹66 Cr₹85 Cr₹81 Cr₹72 Cr₹56 Cr₹70 Cr₹69 Cr
₹3 Cr₹3 Cr₹1 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr
₹81 Cr₹80 Cr₹54 Cr₹55 Cr₹70 Cr₹61 Cr₹43 Cr₹58 Cr₹57 Cr
₹60 Cr₹60 Cr₹45 Cr₹41 Cr₹52 Cr₹46 Cr₹31 Cr₹45 Cr₹43 Cr

Share Price Live Stats

Open (₹)2,171.10
Volume (₹)1.05 L
High (₹)2,294.00
Upper Circuit2,605.30
Low (₹)2,167.90
Lower Circuit1,736.90
Prev Close2,171.10
52W High (₹)2,294.00
Price2,280.00
52W Low (₹)1,336.60

Share Market Cap & Key Ratios Overview

M.Cap (₹)13280.60 Cr
Div. Yield (%)0.46
PE Ratio64.15
Debt to Equity0.19
Price to Book12.74
Book Value122.12
EPS (TTM)33.85
Face Value10.00
ROE (%)27.36

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
CORONANSE
LTP
1W Low
1W High
Market cap (₹)
1769.9-7.8 (-0.44%)
1722
1855
4,24,202Cr
10064+284 (2.90%)
9621.50
10064
2,64,141Cr
4650+36.6 (0.79%)
4532
4675
1,74,402Cr
2323-82.5 (-3.43%)
2206.10
2441.90
1,26,811Cr
1240.6-4.9 (-0.39%)
1182
1254.20
1,23,685Cr
1368.3+16.3 (1.21%)
1336.70
1368.30
1,11,868Cr
1396.9+18 (1.31%)
1357
1396.90
1,11,650Cr
2475-17.8 (-0.71%)
2457.90
2528
1,02,196Cr
1694.5+13.1 (0.78%)
1647.20
1697.40
96,951Cr
2015.9+4.9 (0.24%)
1974
2033.80
91,301Cr
2280+130.4 (6.07%)
2090
2294
13,281Cr

Key Highlights of CORONA Remedies Ltd’s P&L

In 2026-03-31, CORONA Remedies Ltd reported total revenue of ₹1413.83Cr, compared with ₹1202.35Cr in 2025-03-31, reflecting CORONA Remedies Ltd turnover.

Depreciation was ₹37.87Cr and finance costs were ₹6.97Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹240.42Cr in 2026-03-31 as compared to ₹198.53Cr in 2025-03-31.

Net Profit (PAT) was ₹185.12Cr in 2026-03-31 compared with ₹149.43Cr in 2025-03-31.

Earnings per share (EPS) were ₹30.27 in 2026-03-31, compared with ₹24.43 in 2025-03-31.